Arbutus Biopharma Corp
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
British Columbia, Canada
Business Address
701 VETERANS CIRCLE, WARMINSTER, PA, 18974
Mailing Address
701 VETERANS CIRCLE, WARMINSTER, PA, 18974
Phone
604-419-3200
Fiscal Year End
1231
EIN
980597776
Financial Overview
FY2025
-$69.92M
Net Income
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 23, 2026 | View on SEC |
| 8-K Current report of material events | March 23, 2026 | View on SEC |
| 8-K Current report of material events | March 3, 2026 | View on SEC |
| 8-K Current report of material events | February 20, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 11, 2026 | View on SEC |
| 8-K Current report of material events | February 6, 2026 | View on SEC |
| 4 Insider stock transaction report | February 2, 2026 | View on SEC |
| 4 Insider stock transaction report | February 2, 2026 | View on SEC |
| 8-K Current report of material events | January 16, 2026 | View on SEC |
Annual Reports
10-K
March 23, 2026
- Strong LNP (lipid nanoparticle) delivery technology and patent portfolio, central to advanced therapies including mRNA vaccines.
- Ongoing high-stakes lawsuit against Moderna over LNP patents, with potential for billions in damages or royalties.
Material Events
8-K
Legal Issue
March 23, 2026
High Impact
- $2.25 billion settlement with Moderna, including $467.5 million upfront cash for Arbutus expected July 2026.
- Potential for an additional $642.5 million from Moderna contingent on '435 patent appeal.
8-K
Legal Issue
March 3, 2026
High Impact
- Settled patent infringement lawsuit with Moderna, resolving a major legal dispute.
- Secured a guaranteed $950 million cash payment from Moderna.
8-K
Legal Issue
January 16, 2026
High Impact
- The European patent revocation is limited to Europe and does not affect Arbutus's litigation efforts in the U.S., Japan, Canada, or other UPC cases.
- Arbutus maintains a broader, diversified intellectual property strategy across various jurisdictions.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.